<JSK Biomed participated in the 24th Daegyeong Conference of Dermatologic Therapy, held at Hotel Interburgo Daegu, and introduced its needle-free drug delivery medical device, Mirajet.>
JSK Biomed (JSK Biomed Co., Ltd.) announced on the 9th that it participated in the 24th Daegyeong Conference of Dermatologic Therapy, held at Hotel Interburgo Daegu, where it introduced its needle-free drug delivery medical device, Mirajet.
The Daegyeong Conference of Dermatologic Therapy is a leading regional academic event where dermatologists and aesthetic medicine professionals discuss the treatment standards, limitations, and combination therapy strategies encountered in actual clinical practice. This year’s 24th conference covered a range of topics of high interest in dermatology practice, including the practical use of skin boosters, the standards and limitations of pore and scar treatment, and strategies for selecting and combining energy-based devices (EBDs).
In line with these trends, JSK Biomed introduced Mirajet at the event, expanding its points of contact with medical professionals. Mirajet is JSK Biomed’s flagship medical device, employing laser-pressure-based needle-free drug delivery technology. It is designed to deliver drugs into the skin in the form of a microjet using the instantaneous pressure generated by a 2940nm Er:YAG laser, and is expanding its range of applications in drug delivery procedures for skin boosters and various regenerative and skin-texture-improving treatments.
As demand for skin boosters grows, attention is increasingly turning not only to the drugs themselves but also to how they are delivered. Against this backdrop, Mirajet has drawn interest by offering physicians a new treatment option through a needle-free approach that differs from conventional methods, in terms of reducing patient burden and improving procedural workflow.
A JSK Biomed official said, "This year’s Daegyeong Conference of Dermatologic Therapy was a meaningful event in that it allowed for an in-depth discussion of the treatment standards and combination strategies needed in real clinical practice," adding, "Building on its potential for combination with a variety of skin boosters and regenerative treatment materials, Mirajet will continue to evolve into a platform that helps dermatologists design more flexible treatment strategies."
Meanwhile, JSK Biomed has been recognized for its global technological competitiveness, having been selected as a finalist in the ‘Laser & Energy-Based Device’ category at the AMWC 2026 Awards this year. The company is also expanding its supply to tertiary general hospitals such as Seoul National University Bundang Hospital and Kangbuk Samsung Hospital, while strengthening its brand recognition and network through domestic and international academic conferences and hands-on seminars.
FAQ
Q. What is Mirajet?
A. Mirajet is a needle-free drug delivery medical device developed by JSK Biomed. It uses the instantaneous pressure generated by a 2940nm Er:YAG laser to deliver drugs into the skin in a microjet form, without the use of needles.
Q. What treatments can Mirajet be used for?
A. Mirajet can be used for a range of drug delivery procedures, including skin boosters and other regenerative or skin-texture-improving therapies.
Q. What are the advantages of needle-free drug delivery?
A. A needle-free approach can help reduce patient discomfort and burden compared to conventional needle-based injection, while offering physicians a more flexible treatment workflow.
Q. Has Mirajet received international recognition?
A. Yes. JSK Biomed’s Mirajet was selected as a finalist in the ‘Laser & Energy-Based Device’ category at the AMWC 2026 Awards.
Q. Where is Mirajet currently used in Korea?
A. Mirajet’s supply is expanding to tertiary general hospitals in Korea, including Seoul National University Bundang Hospital and Kangbuk Samsung Hospital.
